About Allievex
Allievex is a Healthcare company based in Marblehead (United States) founded in 2017. Developer of therapeutics for rare neurodegenrative diseases. The company has 7 employees. Allievex offers products and services including Tralesinidase Alfa. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is ALLIEVEX CORP. Its competitors include Biogen, Denali Therapeutics and Intra-Cellular Therapies; 3 of its 3 listed competitors have raised funding.
Company details
Allievex is a developer of therapeutics for rare pediatric neurodegenerative diseases. The lead compounds tralesinidase alfa for treating Sanfilippo syndrome Type B (Mucopolysaccharidosis IIIB) in children. Tralesinidase alfa is a fusion of recombinant human alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2) used to restore NAGLU activity in the brain.
- Headquarters Marblehead, United States
- Employees 7
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website allievex.com
- Social LinkedIn X
- Legal Name Allievex Corp.
- InvestorsNovo Holdings
& 1 more
- Employee Count7
Products & Services of Allievex
Allievex offers a comprehensive portfolio of products and services, including Tralesinidase Alfa.
Treatment for Sanfilippo Syndrome Type B via targeted administration.
Funding Insights of Allievex
- Total Rounds 1
- Investors Count 2
All 1 funding rounds of Allievex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | Series A | – | Novo Holdings, Pappas Capital | – |
2 investors in total: 2 institutional.
Investors in Allievex
Allievex has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Novo Holdings and Pappas Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States |
Investor details for Allievex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allievex
6 people are tracked at Allievex (4 in board & advisors, 2 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Kyle Rasbach | Director | Board & advisors |
Martin Edwards | Director | Board & advisors |
Thomas Dyrberg | Director | Board & advisors |
Cookie Yu | Director | Board & advisors |
Alex Nolte | Consultant, Finance | Team |
Thaminda Ramanayake | Consultant, Corporate Development & Strategy | Team |
Complete people profiles for Allievex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Allievex
2 dated milestones of Allievex across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Allievex is founded.
- Funding First funding round.
Competitors of Allievex
Allievex has 3 listed competitors in our database, 3 of them funded. They include Biogen, Denali Therapeutics and Intra-Cellular Therapies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| intracellulartherapies.com | 2002 | New York, United States | $80.87M | 600 | Developer of therapeutics for psychiatric and neurologic diseases |
Detailed competitors of Allievex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pediatrics
3 companies that operate in the same segment as Allievex (Pediatrics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Owlet is recognized for developing FDA-cleared smart baby monitors. | 2013 | Lehi, Utah, United States | USD 54.96 M | USD 105.71 M | 85 | |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Smart baby monitors and sleep tracking solutions are provided. | 2014 | New York, New York, United States | USD 116.6 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Allievex
Allievex was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Allievex is headquartered in Marblehead, United States. It is registered at Marblehead, Massachusetts, United States.
Allievex has 7 employees.
Allievex is a developer of therapeutics for rare pediatric neurodegenerative diseases. The lead compounds tralesinidase alfa for treating Sanfilippo syndrome Type B (Mucopolysaccharidosis IIIB) in children. Tralesinidase alfa is a fusion of recombinant human alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2) used to restore NAGLU activity in the brain.
Allievex's top competitors include Intra-Cellular Therapies, Denali Therapeutics and Biogen.
Allievex offers Tralesinidase Alfa.
Allievex has 2 investors. Key investors include Novo Holdings, and Pappas Capital.
Allievex operates through Allievex Corp..